Vincristine
- Generic Name
- Vincristine
- Brand Names
- Marqibo, Vincasar
- Drug Type
- Small Molecule
- Chemical Formula
- C46H56N4O10
- CAS Number
- 57-22-7
- Unique Ingredient Identifier
- 5J49Q6B70F
- Background
Vincristine is an antitumor vinca alkaloid isolated from Vinca Rosea. It is marketed under several brand names, many of which have different formulations such as Marqibo (liposomal injection) and Vincasar. Vincristine is indicated for the treatment of acute leukaemia, malignant lymphoma, Hodgkin's disease, acute erythraemia, and acute panmyelosis. vincristin...
- Indication
Treatment of acute lymphocytic leukemia (ALL), Hodgkin lymphoma, non-Hodgkin lymphomas, Wilms' tumor, neuroblastoma, rhabdomyosarcoma. Liposomal vincristine is indicated for the treatment of relapsed Philadelphia chromosome-negative (Ph-) acute lymphoblastic leukemia (ALL).
- Associated Conditions
- Acute Lymphoblastic Leukemia (ALL), Choriocarcinoma, Chronic Lymphocytic Leukemia, Ewing's Sarcoma, Gestational Trophoblastic Neoplasia, Hepatoblastomas, Hodgkin's Lymphoma, Immune Thrombocytopenia (ITP), Kaposi's Sarcoma, Multiple Myeloma (MM), Neuroblastoma (NB), Non-Hodgkin's Lymphoma (NHL), Ovarian germ cell tumour, Pheochromocytoma, Relapsed Acute Lymphoblastic Leukemia (ALL), Retinoblastoma, Rhabdomyosarcomas, Small Cell Lung Cancer (SCLC), Wilms' tumor, Advanced Thymoma
- Associated Therapies
- -
R-CHOP Combined With Lenalidomide in the First-line Treatment for Patients With Diffuse Large B Cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2020-01-02
- Last Posted Date
- 2023-12-05
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 60
- Registration Number
- NCT04214626
- Locations
- 🇨🇳
Henan Cancer Hospital/The affiliated Cancer Hospital of ZhengZhou university, Zhengzhou, Henan, China
Venetoclax, SL-401, and Chemotherapy for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm
- Conditions
- Interventions
- First Posted Date
- 2020-01-02
- Last Posted Date
- 2024-07-03
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 40
- Registration Number
- NCT04216524
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Implantable Microdevice for the Delivery of Drugs and Their Effect on Tumors in Patients With Metastatic or Recurrent Sarcoma
- Conditions
- Interventions
- First Posted Date
- 2019-12-13
- Last Posted Date
- 2024-10-15
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 20
- Registration Number
- NCT04199026
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Sintilimab in Combination With R-CHOP in Patients With Treatment-naive EBV-positive DLBCL, NOS
- First Posted Date
- 2019-11-29
- Last Posted Date
- 2019-11-29
- Target Recruit Count
- 55
- Registration Number
- NCT04181489
- Locations
- 🇨🇳
The first Affiliated Hospital Of Nanjing Medical University(JiangSu Province Hospital), NanJing, Jiangsu, China
🇨🇳Drum tower hospital, Nanjing, Jiangsu, China
🇨🇳Xuzhou Central Hospital, Xuzhou, Jiangsu, China
A Study of Daratumumab and Dose-Adjusted EPOCH in Plasmablastic Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2019-10-25
- Last Posted Date
- 2024-10-16
- Lead Sponsor
- AIDS Malignancy Consortium
- Target Recruit Count
- 15
- Registration Number
- NCT04139304
- Locations
- 🇺🇸
University of Miami Miller School of Medicine, Miami, Florida, United States
🇺🇸University of Illinois at Chicago, Chicago, Illinois, United States
🇺🇸Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States
Camrelizumab Combined With AVD in the First-line Treatment for Patients With Advanced Classical Hodgkin's Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2019-08-26
- Last Posted Date
- 2024-05-07
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 60
- Registration Number
- NCT04067037
- Locations
- 🇨🇳
Henan Cancer Hospital/The affiliated Cancer Hospital of ZhengZhou university, Zhengzhou, Henan, China
International Cooperative Treatment Protocol for Children and Adolescents With Lymphoblastic Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2019-08-02
- Last Posted Date
- 2024-07-10
- Lead Sponsor
- University Hospital Muenster
- Target Recruit Count
- 683
- Registration Number
- NCT04043494
- Locations
- 🇳🇱
Princess Maxima Centre for Pediatric Oncology, Utrecht, Netherlands
🇫🇷Unité d'hématologie pédiatrique CHRU de Lille - Hôpital Jeanne de Flandre, Lille, France
🇧🇪UZ Antwerpen Kinderhemato-oncologie, Edegem, Belgium
Biomarker Guided Treatment in DLBCL
- First Posted Date
- 2019-07-19
- Last Posted Date
- 2020-11-19
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 128
- Registration Number
- NCT04025593
- Locations
- 🇨🇳
Ruijin hospital, Shanghai, Shanghai, China
Inotuzumab Ozogamicin and Chemotherapy in Treating Patients With Recurrent or Refractory B-cell Acute Lymphoblastic Leukemia
- Conditions
- Interventions
- First Posted Date
- 2019-06-19
- Last Posted Date
- 2023-07-06
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 24
- Registration Number
- NCT03991884
- Locations
- 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
Phase I Study of Inotuzumab With Augmented BFM Re-Induction for Patients With Relapsed/Refractory B-cell ALL
- Conditions
- Interventions
- First Posted Date
- 2019-05-24
- Last Posted Date
- 2023-08-22
- Lead Sponsor
- University of Virginia
- Target Recruit Count
- 36
- Registration Number
- NCT03962465
- Locations
- 🇺🇸
University of Wisconsin, Madison, Wisconsin, United States
🇺🇸University of Virginia, Charlottesville, Virginia, United States
🇺🇸Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.